%0 Journal Article %T Long Acting Propranolol and HSP-70 Rich Tumor Lysate Reduce Tumor Growth and Enhance Immune Response against Fibrosarcoma in Balb/c Mice %J Iranian Journal of Immunology %I Shiraz Institute for Cancer Research %Z 1735-1383 %A Khalili, Ahmad %A Muhammad Hassan, Zuhair %A Shahabi, Shahram %A Pourfathollah, Ali Akbar %A Ostad, Seyed Nasser %A Noori, Shokoofe %A Mahdavi, Mehdi %A Haybar, Habib %A Langroudi, Ladan %D 2013 %\ 06/01/2013 %V 10 %N 2 %P 70-82 %! Long Acting Propranolol and HSP-70 Rich Tumor Lysate Reduce Tumor Growth and Enhance Immune Response against Fibrosarcoma in Balb/c Mice %K IFN-γ %K IL-4 %K Immune Modulator %K Propranolol %K T Regulatory Cell %R %X Background: Noradrenaline (NA), the principal neurotransmitter released from sympathetic nerve terminals, influences T-cell maturation, not only directly in developing T cells, but also indirectly, by acting on the thymic nonlymphoid cells. In vitro and in vivo studies have demonstrated the anti-proliferative, anti-migratory, antiangiogenic and cytotoxic properties of propranolol, β-AR blocker, against various cancers. Objectives: To evaluate the effect of propranolol on efficacy of HSP-70 rich lysate vaccine in immunotherapy of fibrosarcoma. Methods: Mouse fibrosarcoma WEHI-164 cells were used to immunize tumor-bearing mice with or without propranolol and HSP-70. Splenocytes proliferation, cytotoxic activity of the splenocytes, naturally occurring CD4+ CD25high T-reg cells and IFN-γ and IL-4 secretion as well as tumor size, were assessed to describe the anti-tumor immune response. Results: A significant increase in the level of IFN-γ in the mice vaccinated with WEHI-164 cells enriched with HSP-70 and co-treated with propranolol was observed compared to controls. However, HSP enrichment or propranolol treatment alone did not enhance the immune response as measured by the level of IFN-γ. Likewise, a decrease in tumor growth in the test group (p<0.01) and a significant increase in CTL activity (p<0.05) was observed. Conclusion: HSP enriched vaccine shows anti-tumor activity, probably due to the modulation of immune responses. %U https://iji.sums.ac.ir/article_16811_8a945847531ec52d8ad794bd12bb912c.pdf